Please login to the form below
Cytokinetics
This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
Following the publication of the results, shares in Amgen dropped down by 4.6%, with shares in California-based Cytokinetics falling by 43%. ... Omecamtiv mecarbil, originally developed by Cytokinetics, is designed to increase the duration of cardiac
Latest news
-
Trial of Amgen, Servier’s heart failure drug clears interim check
Originally developed by Cytokinetics, omecamtiv mecarbil is the first in a new class of drugs – dubbed cardiac myosin activators – that are designed to increase the duration of cardiac muscle contractility and
-
Amgen, Servier heart failure drug clears trial hurdle
Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs called cardiac myosin activators, that are designed to increase the duration of cardiac muscle contractility and improve ... Amgen recently started phase 1 trials of
-
Amgen, Servier start second phase 3 trial of heart failure hope
Originally developed by Cytokinetics, omecamtiv is the first in a new class of drugs designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance in heart failure. ... Amgen, Servier and Cytokinetics are
-
Roche reshuffles its executive committee, again
Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.
-
Amgen agrees to take Cytokinetics' heart failure drug into phase III
originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Trial of Amgen, Servier’s heart failure drug clears interim check
Roche reshuffles its executive committee, again
More from news
Approximately 5 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch July 2016
Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
-
Astellas: Ten years young
option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
-
Heart failure therapy embarks on a new era
In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
-
Deal Watch table for December 2014
Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).
Deal Watch February 2017
Astellas: Ten years young
Heart failure therapy embarks on a new era
Deal Watch table for December 2014
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- David Hunt launches independent agency The Considered
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Ashfield Health announces three new senior hires
- The new reality of building a corporate brand in pharma
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
